The DOI matches its Crossref record; 320 of the 320 references it cites were found in a registry or an index.
The Toxicology of Ligands for Peroxisome Proliferator-Activated Receptors (PPAR)
Abstract
Peroxisome proliferator-activated receptors (PPARs) are ligand activated transcription factors that modulate target gene expression in response to endogenous and exogenous ligands. Ligands for the PPARs have been widely developed for the treatment of various diseases including dyslipidemias and diabetes. While targeting selective receptor activation is an established therapeutic approach for the treatment of various diseases, a variety of toxicities are known to occur in response to ligand administration. Whether PPAR ligands produce toxicity via a receptor-dependent and/or off-target-mediated mechanism(s) is not always known. Extrapolation of data derived from animal models and/or in vitro models, to humans, is also questionable. The different toxicities and mechanisms associated with administration of ligands for the three PPARs will be discussed, and important data gaps that could increase our current understanding of how PPAR ligands lead to toxicity will be highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Badawi, A. F., Eldeen, M. B., Liu, Y., Ross, E. A., & Badr, M. Z. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2556 · Cited by 56
RetractedLehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 2×
“In addition to synthetic ligands for PPARs, endogenous compounds have also been shown to bind to and activate PPARs including fatty acids and eicosanoids (Forman et al. 1997; Keller et al. 1993b; Kliewer et al. 1997; Yu et al. 1995).”
BackgroundForman, B. M., Chen, J., & Evans, R. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4312 · Cited by 2,116
PPARγ Is Required for the Differentiation of Adipose Tissue In Vivo and In Vitro
Rosen, E. D., Sarraf, P., Troy, A. E., Bradwin, G., Moore, K., Milstone, D. S., Spiegelman, B. M., & Mortensen, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80211-7 · Cited by 2,079
Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ
Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K., & Milburn, M. V. (1998) · Nature · doi:10.1038/25931 · Cited by 1,958
PPARγ Is Required for Placental, Cardiac, and Adipose Tissue Development
Barak, Y., Nelson, M. C., Ong, E. S., Jones, Y. Z., Ruiz-Lozano, P., Chien, K. R., Koder, A., & Evans, R. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80209-9 · Cited by 1,956
Ward, A., & Clissold, S. P. (1987) · Drugs · doi:10.2165/00003495-198734010-00003 · Cited by 1,754
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Self-citationKliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Barroso, I., Gurnell, M., Crowley, V. E. F., Agostini, M., Schwabe, J. W., Soos, M. A., Maslen, G. L., Williams, T. D. M., Lewis, H., Schafer, A. J., et al. (1999) · Nature · doi:10.1038/47254 · Cited by 1,368
PPARγ Mediates High-Fat Diet–Induced Adipocyte Hypertrophy and Insulin Resistance
Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80210-5 · Cited by 1,342
Peroxisome-Proliferator-Activated Receptor δ Activates Fat Metabolism to Prevent Obesity
Wang, Y.-X., Lee, C.-H., Tiep, S., Yu, R. T., Ham, J., Kang, H., & Evans, R. M. (2003) · Cell · doi:10.1016/s0092-8674(03)00269-1 · Cited by 1,296
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
Pascual, G., Fong, A. L., Ogawa, S., Gamliel, A., Li, A. C., Perissi, V., Rose, D. W., Willson, T. M., Rosenfeld, M. G., & Glass, C. K. (2005) · Nature · doi:10.1038/nature03988 · Cited by 1,254
Peroxisome proliferator-activated receptor a target genes
Mandard, S., M�ller, M., & Kersten, S. (2004) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s00018-003-3216-3 · Cited by 1,218
Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors
Xu, H. E., Lambert, M. H., Montana, V. G., Parks, D. J., Blanchard, S. G., Brown, P. J., Sternbach, D. D., Lehmann, J. M., Wisely, G. B., Willson, T. M., et al. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80467-0 · Cited by 1,169
Maeda, S., Kamata, H., Luo, J.-L., Leffert, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,164
Delerive, P., De Bosscher, K., Besnard, S., Vanden Berghe, W., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Tedgui, A., Haegeman, G., & Staels, B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32048 · Cited by 1,089
Self-citationRegulation of Muscle Fiber Type and Running Endurance by PPARδ
Wang, Y.-X., Zhang, C.-L., Yu, R. T., Cho, H. K., Nelson, M. C., Bayuga-Ocampo, C. R., Ham, J., Kang, H., & Evans, R. M. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020294 · Cited by 1,089
PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs
He, T.-C., Chan, T. A., Vogelstein, B., & Kinzler, K. W. (1999) · Cell · doi:10.1016/s0092-8674(00)81664-5 · Cited by 1,085
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 3×
“2003) and PPAR-independent mechanisms (Chawla et al. 2001; Kim et al. 2005a; Welch et al. 2003).”
BackgroundOliver, W. R., Shenk, J. L., Snaith, M. R., Russell, C. S., Plunket, K. D., Bodkin, N. L., Lewis, M. C., Winegar, D. A., Sznaidman, M. L., Lambert, M. H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091021198 · Cited by 1,046
Differentiation and reversal of malignant changes in colon cancer through PPARγ
Sarraf, P., Mueller, E., Jones, D., King, F. J., DeAngelo, D. J., Partridge, J. B., Holden, S. A., Chen, L. B., Singer, S., Fletcher, C., et al. (1998) · Nature Medicine · doi:10.1038/2030 · Cited by 988
He, W., Barak, Y., Hevener, A., Olson, P., Liao, D., Le, J., Nelson, M., Ong, E., Olefsky, J. M., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2536828100 · Cited by 976
Keller, H., Dreyer, C., Medin, J., Mahfoudi, A., Ozato, K., & Wahli, W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2160 · Cited by 948
The Developmental Toxicity of Perfluoroalkyl Acids and Their Derivatives
Lau, C., Butenhoff, J. L., & Rogers, J. M. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2003.11.031 · Cited by 867
Terminal Differentiation of Human Breast Cancer through PPARγ
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 851
Tanaka, T., Yamamoto, J., Iwasaki, S., Asaba, H., Hamura, H., Ikeda, Y., Watanabe, M., Magoori, K., Ioka, R. X., Tachibana, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0306981100 · Cited by 832
Critical tables for calculating the cholesterol saturation of native bile.
Carey, M. C. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40677-7 · Cited by 794
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witztum, J. L., Auwerx, J., Palinski, W., & Glass, C. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7614 · Cited by 721
Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids
Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M., & Lazar, M. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23975 · Cited by 711
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Mechanisms of phthalate ester toxicity in the female reproductive system.
Lovekamp-Swan, T., & Davis, B. J. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.5658 · Cited by 645
Peters, J. M., Lee, S. S. T., Li, W., Ward, J. M., Gavrilova, O., Everett, C., Reitman, M. L., Hudson, L. D., & Gonzalez, F. J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5119-5128.2000 · Cited by 633
Self-citationStructural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARα
Xu, H. E., Stanley, T. B., Montana, V. G., Lambert, M. H., Shearer, B. G., Cobb, J. E., McKee, D. D., Galardi, C. M., Plunket, K. D., Nolte, R. T., et al. (2002) · Nature · doi:10.1038/415813a · Cited by 613
Lefebvre, A.-M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J.-C., Geboes, K., Briggs, M., Heyman, R., & Auwerx, J. (1998) · Nature Medicine · doi:10.1038/2036 · Cited by 611
PPARα Agonist-Induced Rodent Tumors: Modes of Action and Human Relevance
Klaunig, J. E., Babich, M. A., Baetcke, K. P., Cook, J. C., Corton, J. C., David, R. M., DeLuca, J. G., Lai, D. Y., McKee, R. H., Peters, J. M., et al. (2003) · Critical Reviews in Toxicology · doi:10.1080/713608372 · Cited by 611
Self-citationGuan, Y., Hao, C., Cha, D. R., Rao, R., Lu, W., Kohan, D. E., Magnuson, M. A., Redha, R., Zhang, Y., & Breyer, M. D. (2005) · Nature Medicine · doi:10.1038/nm1278 · Cited by 608
Notterman, D. A., Alon, U., Sierk, A. J., & Levine, A. J. (2001) · PubMed · Cited by 606
Activators of the nuclear receptor PPARγ enhance colon polyp formation
Saez, E., Tontonoz, P., Nelson, M. C., Alvarez, J. G. A., U, T. M., Baird, S. M., Thomazy, V. A., & Evans, R. M. (1998) · Nature Medicine · doi:10.1038/2042 · Cited by 587
Barak, Y., Liao, D., He, W., Ong, E. S., Nelson, M. C., Olefsky, J. M., Boland, R., & Evans, R. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012610299 · Cited by 586
Matsusue, K., Haluzik, M., Lambert, G., Yim, S.-H., Gavrilova, O., Ward, J. M., Brewer, B., Reitman, M. L., & Gonzalez, F. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317223 · Cited by 585
Self-citationPeroxisome Proliferator–Activated Receptor γ and Metabolic Disease
Willson, T. M., Lambert, M. H., & Kliewer, S. A. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.341 · Cited by 582
Transcriptional Repression of Atherogenic Inflammation: Modulation by PPARδ
Lee, C.-H., Chawla, A., Urbiztondo, N., Liao, D., Boisvert, W. A., & Evans, R. M. (2003) · Science · doi:10.1126/science.1087344 · Cited by 580
Gampe, R. T., Montana, V. G., Lambert, M. H., Miller, A. B., Bledsoe, R. K., Milburn, M. V., Kliewer, S. A., Willson, T. M., & Xu, H. E. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)80448-7 · Cited by 574
Exposure to Perfluorooctane Sulfonate during Pregnancy in Rat and Mouse. II: Postnatal Evaluation
Lau, C., Thibodeaux, J. R., Hanson, R. G., Rogers, J. M., Grey, B. E., Stanton, M. E., Butenhoff, J. L., & Stevenson, L. A. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg122 · Cited by 549
Xu, H. E., Lambert, M. H., Montana, V. G., Plunket, K. D., Moore, L. B., Collins, J. L., Oplinger, J. A., Kliewer, S. A., Gampe, R. T., McKee, D. D., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241410198 · Cited by 538
Rousseaux, C., Lefebvre, B., Dubuquoy, L., Lefebvre, P., Romano, O., Auwerx, J., Metzger, D., Wahli, W., Desvergne, B., Naccari, G. C., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041948 · Cited by 526
Azziz, R., Ehrmann, D., Legro, R. S., Whitcomb, R. W., Hanley, R., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.4.7375 · Cited by 517
Activation of PPAR and PPAR by Environmental Phthalate Monoesters
Hurst, C. H., & Waxman, D. J. (2003) · Toxicological Sciences · doi:10.1093/toxsci/kfg145 · Cited by 510
Peters, J. (1997) · Carcinogenesis · doi:10.1093/carcin/18.11.2029 · Cited by 479
Self-citationPeroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Braissant, O., & Wahli, W. (1998) · Endocrinology · doi:10.1210/en.139.6.2748 · Cited by 454
Cheng, L., Ding, G., Qin, Q., Huang, Y., Lewis, W., He, N., Evans, R. M., Schneider, M. D., Brako, F. A., Xiao, Y., et al. (2004) · Nature Medicine · doi:10.1038/nm1116 · Cited by 453
Peroxisome proliferator-activated receptor γ in diabetes and metabolism
Rangwala, S. M., & Lazar, M. A. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.03.012 · Cited by 450
Hepatic Dysfunction Associated with Troglitazone
Watkins, P. B., & Whitcomb, R. W. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381314 · Cited by 446
Welch, J. S., Ricote, M., Akiyama, T. E., Gonzalez, F. J., & Glass, C. K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031789100 · Cited by 429
Self-citationAlterations in Lipoprotein Metabolism in Peroxisome Proliferator-activated Receptor α-deficient Mice
Peters, J. M., Hennuyer, N., Staels, B., Fruchart, J.-C., Fievet, C., Gonzalez, F. J., & Auwerx, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.43.27307 · Cited by 429
Self-citationBerger, J., Leibowitz, M. D., Doebber, T. W., Elbrecht, A., Zhang, B., Zhou, G., Biswas, C., Cullinan, C. A., Hayes, N. S., Li, Y., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6718 · Cited by 410
Gupta, R. A., Tan, J., Krause, W. F., Geraci, M. W., Willson, T. M., Dey, S. K., & DuBois, R. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13275 · Cited by 401
Critical roles of PPARβ/δ in keratinocyte response to inflammation
Tan, N. S., Michalik, L., Noy, N., Yasmin, R., Pacot, C., Heim, M., Flühmann, B., Desvergne, B., & Wahli, W. (2001) · Genes & Development · doi:10.1101/gad.207501 · Cited by 398
A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.
Caldwell, S. H., Hespenheide, E. E., Redick, J. A., Iezzoni, J. C., Battle, E. H., & Sheppard, B. L. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03553.x · Cited by 394
Di-(2-ethylhexyl) Phthalate Suppresses Estradiol and Ovulation in Cycling Rats
Davis, B. J., Maronpot, R. R., & Heindel, J. J. (1994) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1994.1200 · Cited by 387
Imai, T., Takakuwa, R., Marchand, S., Dentz, E., Bornert, J.-M., Messaddeq, N., Wendling, O., Mark, M., Desvergne, B., Wahli, W., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400356101 · Cited by 383
Azziz, R. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.4.1626 · Cited by 376
trans-Activation of PPARα and PPARγ by Structurally Diverse Environmental Chemicals
Maloney, E. K., & Waxman, D. J. (1999) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8809 · Cited by 374
Akiyama, T. E., Sakai, S., Lambert, G., Nicol, C. J., Matsusue, K., Pimprale, S., Lee, Y.-H., Ricote, M., Glass, C. K., Brewer, H. B., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2607-2619.2002 · Cited by 368
Self-citationDi-Poı̈, N., Tan, N. S., Michalik, L., Wahli, W., & Desvergne, B. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00646-9 · Cited by 327
Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J., & Yang, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501744102 · Cited by 317
Self-citationTsubouchi, Y., Sano, H., Kawahito, Y., Mukai, S., Yamada, R., Kohno, M., Inoue, K.-I., Hla, T., & Kondo, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2436 · Cited by 315
Sznaidman, M. L., Haffner, C. D., Maloney, P. R., Fivush, A., Chao, E., Goreham, D., Sierra, M. L., LeGrumelec, C., Xu, H. E., Montana, V. G., et al. (2003) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(03)00207-5 · Cited by 312
Activation of PPARδ alters lipid metabolism in db/db mice
Leibowitz, M. D., Fiévet, C., Hennuyer, N., Peinado-Onsurbe, J., Duez, H., Berger, J., Cullinan, C. A., Sparrow, C. P., Baffic, J., Berger, G. D., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01554-4 · Cited by 308
PPARδ is a very low-density lipoprotein sensor in macrophages
Chawla, A., Lee, C.-H., Barak, Y., He, W., Rosenfeld, J., Liao, D., Han, J., Kang, H., & Evans, R. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337331100 · Cited by 305
Ricote, M., Huang, J. T., Welch, J. S., & Glass, C. K. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.5.733 · Cited by 304
Shi, Y., Hon, M., & Evans, R. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052707099 · Cited by 303
Palakurthi, S. S., Aktaş, H., Grubissich, L., Mortensen, R. M., & Halperin, J. A. (2001) · PubMed · Cited by 302
Corepressors selectively control the transcriptional activity of PPARγ in adipocytes
Guan, H.-P., Ishizuka, T., Chui, P. C., Lehrke, M., & Lazar, M. A. (2005) · Genes & Development · doi:10.1101/gad.1263305 · Cited by 293
Hepatic Stellate Cells: Unique Characteristics in Cell Biology and Phenotype
Sato, M., Suzuki, S., & Senoo, H. (2003) · Cell Structure and Function · doi:10.1247/csf.28.105 · Cited by 291
APC-dependent suppression of colon carcinogenesis by PPARγ
Girnun, G. D., Smith, W. M., Drori, S., Sarraf, P., Mueller, E., Eng, C., Nambiar, P., Rosenberg, D. W., Bronson, R. T., Edelmann, W., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162480299 · Cited by 277
Self-citationFu, M., Rao, M., Bouras, T., Wang, C., Wu, K., Zhang, X., Li, Z., Yao, T.-P., & Pestell, R. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500403200 · Cited by 276
Receptor-independent actions of PPAR thiazolidinedione agonists: Is mitochondrial function the key?
Feinstein, D. L., Spagnolo, A., Akar, C., Weinberg, G., Murphy, P., Gavrilyuk, V., & Russo, C. D. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2005.03.033 · Cited by 275
Gupta, R. A., Wang, D., Katkuri, S., Wang, H., Dey, S. K., & DuBois, R. N. (2004) · Nature Medicine · doi:10.1038/nm993 · Cited by 275
Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., & Hosokawa, M. (2001) · PubMed · Cited by 270
Gurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T. N., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J. W., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5754 · Cited by 264
Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ
Uppenberg, J., Svensson, C., Jaki, M., Bertilsson, G., Jendeberg, L., & Berkenstam, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31108 · Cited by 260
Knouff, C., & Auwerx, J. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0036 · Cited by 256
Asakawa, M., Takano, H., Nagai, T., Uozumi, H., Hasegawa, H., Kubota, N., Saito, T., Masuda, Y., Kadowaki, T., & Komuro, I. (2002) · Circulation · doi:10.1161/hc1002.105225 · Cited by 255
Duan, S. Z., Ivashchenko, C. Y., Russell, M. W., Milstone, D. S., & Mortensen, R. M. (2005) · Circulation Research · doi:10.1161/01.res.0000179226.34112.6d · Cited by 251
Ward, J. M., Peters, J. M., Perella, C. M., & Gonzalez, F. J. (1998) · Toxicologic Pathology · doi:10.1177/019262339802600208 · Cited by 249
Self-citationPeroxisome proliferator-activated receptor-α and liver cancer: where do we stand?
Peters, J. M., Cheung, C., & Gonzalez, F. J. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0678-9 · Cited by 248
Self-citationGenetic disruption of PPAR δ decreases the tumorigenicity of human colon cancer cells
Park, B. H., Vogelstein, B., & Kinzler, K. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051630998 · Cited by 247
Westergaard, M., Henningsen, J., Kratchmarova, I., Kristiansen, K., Svendsen, M. L., Johansen, C., Jensen, U. B., Schrøder, H. D., Berge, R. K., Iversen, L., et al. (2001) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2001.01329.x · Cited by 241
Schmuth, M., Haqq, C. M., Cairns, W. J., Holder, J. C., Dorsam, S., Chang, S., Lau, P., Fowler, A. J., Chuang, G., Moser, A. H., et al. (2004) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2004.22412.x · Cited by 233
Bility, M. T. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh253 · Cited by 231
Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone
Gitlin, N., Julie, N. L., Spurr, C. L., Lim, K. N., & Juarbe, H. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00008 · Cited by 230
Suh, N., Wang, Y., Williams, C. R., Risingsong, R., Gilmer, T. M., Willson, T. M., & Sporn, M. B. (1999) · PubMed · Cited by 230
Functional PPAR-γ receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas
Heaney, A. P., Fernando, M., Yong, W. H., & Melmed, S. (2002) · Nature Medicine · doi:10.1038/nm784 · Cited by 226
Sato, H., Ishihara, S., Kawashima, K., Moriyama, N., Suetsugu, H., Kazumori, H., Okuyama, T., Rumi, M. A. K., Fukuda, R., Nagasue, N., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1457 · Cited by 225
You, M., & Crabb, D. W. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00056.2004 · Cited by 225
Shimada, T., Kojima, K., Yoshiura, K., Hiraishi, H., & Terano, A. (2002) · Gut · doi:10.1136/gut.50.5.658 · Cited by 222
Levak-Frank, S., Radner, H., Walsh, A., Stollberger, R., Knipping, G., Hoefler, G., Sattler, W., Weinstock, P. H., Breslow, J. L., & Zechner, R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118145 · Cited by 218
Yang, W.-L. (2001) · Carcinogenesis · doi:10.1093/carcin/22.9.1379 · Cited by 218
Post, S. M., Duez, H., Gervois, P. P., Staels, B., Kuipers, F., & Princen, H. M. G. (2001) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/hq1101.098228 · Cited by 217
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J. S., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216
Cheung, C., Akiyama, T. E., Ward, J. M., Nicol, C. J., Feigenbaum, L., Vinson, C., & Gonzalez, F. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0322 · Cited by 215
Self-citationPeroxisome proliferator-activated receptor ? protects against alcohol-induced liver damage
Nakajima, T., Kamijo, Y., Tanaka, N., Sugiyama, E., Tanaka, E., Kiyosawa, K., Fukushima, Y., Peters, J. M., Gonzalez, F. J., & Aoyama, T. (2004) · Hepatology · doi:10.1002/hep.20399 · Cited by 214
Self-citationPeroxisome proliferator–activated receptor-δ attenuates colon carcinogenesis
Harman, F. S., Nicol, C. J., Marin, H. E., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2004) · Nature Medicine · doi:10.1038/nm1026 · Cited by 213
Self-citationMyopathy and rhabdomyolysis with lipid-lowering drugs
Hodel, C. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(02)00010-3 · Cited by 213
Hepatic Failure in a Patient Taking Rosiglitazone
Forman, L. M., Simmons, D. A., & Diamond, R. H. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00005 · Cited by 212
Wang, N., Verna, L., Chen, N.-G., Chen, J., Li, H., Forman, B. M., & Stemerman, M. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203436200 · Cited by 208
Balfour, J. A., McTavish, D., & Heel, R. C. (1990) · Drugs · doi:10.2165/00003495-199040020-00007 · Cited by 204
Avis, I., Hong, S. H., Martínez, A., Moody, T., Choi, Y. H., Trepel, J., Das, R., Jett, M., & Mulshine, J. L. (2001) · The FASEB Journal · doi:10.1096/fj.00-0866fje · Cited by 202
Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report
Al-Salman, J., Arjomand, H., Kemp, D. G., & Mittal, M. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-2-200001180-00006 · Cited by 196
Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report
Neuschwander-Tetri, B. A., Isley, W. L., Oki, J. C., Ramrakhiani, S., Quiason, S. G., Phillips, N. J., & Brunt, E. M. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-1-199807010-00009 · Cited by 195
Keshamouni, V. G., Reddy, R. C., Arenberg, D. A., Joel, B., Thannickal, V. J., Kalemkerian, G. P., & Standiford, T. J. (2004) · Oncogene · doi:10.1038/sj.onc.1206885 · Cited by 195
Yamamoto, K., Ohki, R., Lee, R. T., Ikeda, U., & Shimada, K. (2001) · Circulation · doi:10.1161/hc4001.097186 · Cited by 194
Holst, D., Luquet, S., Nogueira, V., Kristiansen, K., Leverve, X., & Grimaldi, P. A. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00071-4 · Cited by 193
Schaiff, W. T., Carlson, M. G., Smith, S. D., Levy, R., Nelson, D. M., & Sadovsky, Y. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6885 · Cited by 189
The reproductive toxicology of ammonium perfluorooctanoate (APFO) in the rat
Butenhoff, J. L., Kennedy, G. L., Frame, S. R., O’Connor, J. C., & York, R. G. (2004) · Toxicology · doi:10.1016/j.tox.2003.11.005 · Cited by 188
Acute Muscular Syndrome Associated with Administration of Clofibrate
Langer, T., & Levy, R. I. (1968) · New England Journal of Medicine · doi:10.1056/nejm196810172791604 · Cited by 188
PPAR ? agonists stimulate oligodendrocyte differentiation in tissue culture
Saluja, I., Granneman, J. G., & Skoff, R. P. (2001) · Glia · doi:10.1002/1098-1136(200103)33:3<191::aid-glia1018>3.0.co;2-m · Cited by 186
PPAR-γ receptor ligands: novel therapy for pituitary adenomas
Heaney, A. P., Fernando, M., & Melmed, S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16575 · Cited by 184
Phosphorylation of PPARs: from molecular characterization to physiological relevance
Diradourian, C., Girard, J., & Pégorier, J.-P. (2005) · Biochimie · doi:10.1016/j.biochi.2004.11.010 · Cited by 178
PLANAVILA, A., RODRIGUEZCALVO, R., JOVE, M., MICHALIK, L., WAHLI, W., LAGUNA, J., & VAZQUEZCARRERA, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.11.011 · Cited by 173
Guan, Y.-F., Zhang, Y.-H., Breyer, R. M., Davis, L., & Breyer, M. D. (1999) · Neoplasia · doi:10.1038/sj.neo.7900050 · Cited by 173
trans-Activation of PPAR and Induction of PPAR Target Genes by Perfluorooctane-Based Chemicals
Shipley, J. M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh130 · Cited by 169
Morimura, K., Cheung, C., Ward, J. M., Reddy, J. K., & Gonzalez, F. J. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi329 · Cited by 168
Self-citationCorton, J. C., & Lapinskas, P. J. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi011 · Cited by 168
Peters, J. (1998) · Carcinogenesis · doi:10.1093/carcin/19.11.1989 · Cited by 161
Self-citationChen, A., & Xu, J. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00209.2004 · Cited by 158
Burdick, A. D., Kim, D. J., Peraza, M. A., Gonzalez, F. J., & Peters, J. M. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2005.07.009 · Cited by 156
Self-citationSeimandi, M., Lemaire, G., Pillon, A., Perrin, A., Carlavan, I., Voegel, J. J., Vignon, F., Nicolas, J., & Balaguer, P. (2005) · Analytical Biochemistry · doi:10.1016/j.ab.2005.06.010 · Cited by 153
Tyl, R. W., Price, C. J., Marr, M. C., & Kimmel, C. A. (1988) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(88)90286-2 · Cited by 153
Padilla, J., Kaur, K., Cao, H., Smith, T. J., & Phipps, R. P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6941 · Cited by 150
Bouskila, M., Pajvani, U. B., & Scherer, P. E. (2005) · International Journal of Obesity · doi:10.1038/sj.ijo.0802908 · Cited by 149
PPARβ/δ selectively induces differentiation and inhibits cell proliferation
Kim, D. J., Bility, M. T., Billin, A. N., Willson, T. M., Gonzalez, F. J., & Peters, J. M. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401713 · Cited by 149
Self-citationNiho, N., Takahashi, M., Kitamura, T., Shoji, Y., Itoh, M., Noda, T., Sügimura, T., & Wakabayashi, K. (2003) · PubMed · Cited by 148
Butler, R., Mitchell, S. H., Tindall, D. J., & Young, C. Y. (2000) · PubMed · Cited by 147
Heller, F., & Harvengt, C. (1983) · European Journal of Clinical Pharmacology · doi:10.1007/bf00544015 · Cited by 141
Suchanek, K. M., May, F. J., Robinson, J. A., Lee, W. J., Holman, N. A., Monteith, G. R., & Roberts‐Thomson, S. J. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10061 · Cited by 140
Huang, J., Shiau, C., Yang, Y.-T. C., Kulp, S. K., Chen, K., Brueggemeier, R. W., Shapiro, C. L., & Chen, C. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.007732 · Cited by 139
Hellemans, K., Michalik, L., Dittie, A., Knorr, A., Rombouts, K., de Jong, J., Heirman, C., Quartier, E., Schuit, F., Wahli, W., et al. (2003) · Gastroenterology · doi:10.1053/gast.2003.50015 · Cited by 137
Chen, L.-C., Hao, C., Chiu, Y. S. Y., Wong, P., Melnick, J., Brotman, M., Moretto, J. C., Mendes, F., Smith, A. P., Bennington, J. L., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3264 · Cited by 137
Wick, M. J., Hurteau, G., Dessev, C., Chan, D. C. F., Geraci, M. W., Winn, R. A., Heasley, L. E., & Nemenoff, R. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.5.1207 · Cited by 135
Sharma, C., Pradeep, A., Wong, L., Rana, A., & Rana, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403143200 · Cited by 130
COMPLICATIONS DURING CLOFIBRATE TREATMENT OF NEPHROTIC-SYNDROME HYPERLIPOPROTEINÆMIA
Bridgman, J. F., Rosen, S. M., & Thorp, J. M. (1972) · The Lancet · doi:10.1016/s0140-6736(72)91905-8 · Cited by 130
Hays, T., Rusyn, I., Burns, A., Kennett, M. J., Ward, J. M., Gonzalez, F. J., & Peters, J. M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh285 · Cited by 130
Self-citationAnti-inflammatory effect of fibrate protects from cisplatin-induced ARF
Li, S., Gökden, N., Okusa, M. D., Bhatt, R., & Portilla, D. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00038.2005 · Cited by 126
Risk of adverse events with fibrates*
Alsheikh-Ali, A. A. A., Kuvin, J. T., & Karas, R. H. (2004) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.06.033 · Cited by 125
Prostacyclin-dependent Apoptosis Mediated by PPARδ
Hatae, T., Wada, M., Yokoyama, C., Shimonishi, M., & Tanabe, T. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107180200 · Cited by 124
Effects of pioglitazone on calcium channels in vascular smooth muscle.
Zhang, F., Sowers, J. R., Ram, J. L., Standley, P. R., & Peuler, J. D. (1994) · Hypertension · doi:10.1161/01.hyp.24.2.170 · Cited by 123
Akiyama, T. E., Nicol, C. J. B., Fiévet, C., Staels, B., Ward, J. M., Auwerx, J. H., Lee, S. S. T., Gonzalez, F. J., & Peters, J. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107073200 · Cited by 122
Self-citationPPAR influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis
Nicol, C. J. B. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh160 · Cited by 120
Keshamouni, V. G., Arenberg, D. A., Reddy, R. C., Newstead, M. J., Anthwal, S., & Standiford, T. J. (2005) · Neoplasia · doi:10.1593/neo.04601 · Cited by 118
Orner, G. A. (2003) · Carcinogenesis · doi:10.1093/carcin/24.2.263 · Cited by 118
Satoh, T., Toyoda, M., Hoshino, H., Monden, T., Yamada, M., Shimizu, H., Miyamoto, K., & Mori, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205279 · Cited by 115
Fenofibrate Impairs Rat Mitochondrial Function by Inhibition of Respiratory Complex I
Brunmair, B., Lest, A., Staniek, K., Gras, F., Scharf, N., Roden, M., Nohl, H., Waldhäusl, W. K., & Fürnsinn, C. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.068312 · Cited by 114
PPARδ status and Apc-mediated tumourigenesis in the mouse intestine
Reed, K. R., Sansom, O. J., Hayes, A. J., Gescher, A. J., Winton, D. J., Peters, J. M., & Clarke, A. R. (2004) · Oncogene · doi:10.1038/sj.onc.1208143 · Cited by 113
Self-citationMimetics of Caloric Restriction Include Agonists of Lipid-activated Nuclear Receptors
Corton, J. C., Apte, U. M., Anderson, S. P., Limaye, P. B., Yoon, L., Latendresse, J. R., Dunn, C. S., Everitt, J. I., Voss, K. A., Swanson, C. L., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406739200 · Cited by 113
Singh, A. R., Lawrence, W. H., & Autian, J. (1974) · Toxicology and Applied Pharmacology · doi:10.1016/0041-008x(74)90159-8 · Cited by 112
Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma.
Haydon, R. C., Zhou, L., Tao, F., Breyer, B. N., Cheng, H., Jiang, W., Ishikawa, A., Peabody, T. D., MONTAG, A. G., Simon, M. A., et al. (2002) · PubMed · Cited by 110
Fauconnet, S., Lascombe, I., Chabannes, É., Adessi, G., Desvergne, B., Wahli, W., & Bittard, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200172200 · Cited by 109
Pioglitazone Prevents Early-Phase Hepatic Fibrogenesis Caused by Carbon Tetrachloride
Kon, K., Ikejima, K., Hirose, M., Yoshikawa, M., Enomoto, N., Kitamura, T., Takei, Y., & Sato, N. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6385 · Cited by 109
Inflammation and cancer: the long reach of Ras
Karin, M. (2005) · Nature Medicine · doi:10.1038/nm0105-20 · Cited by 109
Effects of Troglitazone on HepG2 Viability and Mitochondrial Function
Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., & Schwartz, L. W. (2002) · Toxicological Sciences · doi:10.1093/toxsci/69.1.131 · Cited by 109
Devasthale, P. V., Chen, S., Jeon, Y. T., Qu, F., Shao, C., Wang, W., Zhang, H., Cap, M., Farrelly, D., Golla, R., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0496436 · Cited by 108
Yoshizumi, T., Ohta, T., Ninomiya, I., Terada, I., Fushida, S., Fujimura, T., Nishimura, G., Shimizu, K., Yi, S., & Miwa, K. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.631 · Cited by 107
Yoshimura, R., Matsuyama, M., Segawa, Y., Hase, T., Mitsuhashi, M., Tsuchida, K., Wada, S., Kawahito, Y., Sano, H., & Nakatani, T. (2003) · International Journal of Cancer · doi:10.1002/ijc.10980 · Cited by 104
Hic-5 regulates an epithelial program mediated by PPARγPreprint
Drori, S., Girnun, G. D., Tou, L., Szwaya, J. D., Mueller, E., Kia, X., Shivdasani, R. A., & Spiegelman, B. M. (2005) · Genes & Development · doi:10.1101/gad.1240705 · Cited by 103
Han, S., Sidell, N., Fisher, P. B., & Roman, J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0985 · Cited by 102
Recent Advances in Peroxisome Proliferator-Activated Receptor Science
Shearer, B. G., & Hoekstra, W. J. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033368295 · Cited by 102
Teratogenicity of Di(2-ethylhexyl) Phthalate (DEHP) and Di-n-butyl Phthalate (DBP) in Mice
Shiota, K., & Nishimura, H. (1982) · Environmental Health Perspectives · doi:10.1289/ehp.824565 · Cited by 101
Gardner, O., Dewar, B. J., & Graves, L. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.012260 · Cited by 99
Luquet, S. H., López‐Soriano, J., Holst, D., Gaudel, C., Jehl-Piétri, C., Fredenrich, A., & Grimaldi, P. A. (2004) · Biochimie · doi:10.1016/j.biochi.2004.09.024 · Cited by 98
Akiyama, T. E., Lambert, G., Nicol, C. J., Matsusue, K., Peters, J. M., Brewer, H. B., & Gonzalez, F. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312802200 · Cited by 97
Self-citationShao, J., Sheng, H., & DuBois, R. N. (2002) · PubMed · Cited by 97
Kim, D. J., Akiyama, T. E., Harman, F. S., Burns, A., Shan, W., Ward, J. M., Kennett, M. J., Gonzalez, F. J., & Peters, J. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312063200 · Cited by 95
Self-citationLi, S., Bhatt, R., Megyesi, J. K., Gökden, N., Shah, S. V., & Portilla, D. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00206.2004 · Cited by 94
Li, S., Wu, P., Yarlagadda, P., Vadjunec, N. M., Proia, A. D., Harris, R. A., & Portilla, D. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00190.2003 · Cited by 92
Galli, A., Ceni, E., Crabb, D. W., Mello, T., Salzano, R., Grappone, C., Milani, S., Surrenti, E., Surrenti, C., & Casini, A. (2004) · Gut · doi:10.1136/gut.2003.031997 · Cited by 91
Piva, R., Gianferretti, P., Ciucci, A., Taulli, R., Belardo, G., & Santoro, M. (2004) · Blood · doi:10.1182/blood-2004-04-1360 · Cited by 91
Song, J., Walsh, M. F., Igwe, R. C., et al. (1997) · Diabetes · doi:10.2337/diab.46.4.659 · Cited by 90
Cardiac teratogenesis of halogenated hydrocarbon—Contaminated drinking water
Dawson, B. V., Johnson, P. D., Goldberg, S. J., & Ulreich, J. B. (1993) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(93)90325-u · Cited by 90
Niho, N., Takahashi, M., Shoji, Y., Takeuchi, Y., Matsubara, S., Sügimura, T., & Wakabayashi, K. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01385.x · Cited by 89
Molecular Design, Synthesis, and Hypoglycemic Activity of a Series of Thiazolidine-2,4-diones
Oguchi, M., Wada, K., Honma, H., Tanaka, A., Kaneko, T., Sakakibara, S., Ohsumi, J., Serizawa, N., Fujiwara, T., Horikoshi, H., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990522t · Cited by 88
Mitwally, M. F., Kuşçu, N. K., & Yalcinkaya, T. M. (1999) · Human Reproduction · doi:10.1093/humrep/14.11.2700 · Cited by 88
Wallace, J. M., Schwarz, M., Coward, P., Houze, J. B., Sawyer, J. K., Kelley, K. L., Chai, A., & Rudel, L. L. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m500002-jlr200 · Cited by 88
Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites
Sérée, E., Villard, P., Pascussi, J., Pineau, T., Maurel, P., N'Guyen, Q.-B., Fallone, F., Martin, P., Champion, S., Lacarelle, B., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.023 · Cited by 87
Inoue, K., Kawahito, Y., Tsubouchi, Y., Kohno, M., Yoshimura, R., Yoshikawa, T., & Sano, H. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5640 · Cited by 86
Peters, J. M., Taubeneck, M. W., Keen, C. L., & Gonzalez, F. J. (1997) · Teratology · doi:10.1002/(sici)1096-9926(199711)56:5<311::aid-tera4>3.0.co;2-# · Cited by 86
Self-citation
Cited by
Targeting metabolic dysregulation for fibrosis therapy
Zhao, X., Kwan, J. Y. Y., Yip, K., Liu, P. P., & Liu, F.-F. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0040-5 · Cited by 513
The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention
Peters, J. M., Shah, Y. M., & Gonzalez, F. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3214 · Cited by 492
Self-citationTakacs, M. L., & Abbott, B. D. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfl135 · Cited by 396
Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., & Peters, J. M. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfq338 · Cited by 369
Self-citationModes of Action and Species-Specific Effects of Di-(2-ethylhexyl)Phthalate in the Liver
Rusyn, I., Peters, J. M., & Cunningham, M. L. (2006) · Critical Reviews in Toxicology · doi:10.1080/10408440600779065 · Cited by 301
Self-citation
Metadata
- Authors
- Peraza, M. A., Burdick, A. D., Marin, H. E., Gonzalez, F. J., & Peters, J. M.
- Venue
- Toxicological Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-12-01
- Volume
- 90
- Issue
- 2
- Pages
- 269-295
- ISSN
- 1096-0929 (ISSN-L)
- 1096-6080
- OpenAlex
- W2170985017
- Cited by
- 254
- References
- 320
- FWCI
- 7.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.